Percutaneous and surgical therapies for septal reduction for hypertrophic cardiomyopathy
have been going head‐to‐head for the past 20 years with similar outcomes and mortality …

Hypertrophic cardiomyopathy (HCM) is a genetic disorder caused by pathogenic variants in
sarcomeric genes, leading to left ventricular hypertrophy and complex phenotypic …

Transcatheter mitral valve replacement (TMVR) risks left ventricular outflow tract (LVOT)
obstruction from permanent displacement of the anterior leaflet or the implant itself in cases …

Hypertrophic cardiomyopathy (HCM) is a common contemporary, treatable, genetic disorder
that can be compatible with normal longevity. While current medical therapies are …

Summary MIRTH (Myocardial Intramural Remodeling by Transvenous Tether) is a
transcatheter ventricular remodeling procedure. A transvenous tension element is placed …

Hypertrophic cardiomyopathy (HCM) is a highly treatable monogenetic disorder affecting
nearly 0.2% of the population. The high burden of this disease demands suitable measures …

Background Left ventricular outflow tract (LVOT) obstruction is a source of morbidity in
hypertrophic cardiomyopathy (HCM) and a life-threatening complication of transcatheter …

Transcatheter electrosurgery describes the ability to cut and traverse tissue, at a distance,
without an open surgical field and is possible using either purpose-built or off-the-shelf …

Background Deep intramural ventricular tachycardia substrate targets are difficult to access,
map, and ablate from endocardial and epicardial surfaces, resulting in high recurrence …

Background Intramyocardial guidewire navigation is a novel technique that allows free
transcatheter movement within ventricular muscle. Guidewire radial depth, between …